Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | FLT1 | P17948 | 4/20 | 0.40 |
| ▸ | TYK2 | P29597 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | FDPS | P14324 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3939158 | 0.87 | FLT1 (0.48) | NPC1RAB9AFLT1TYK2MAPT | |
| SCHEMBL4068884 | 0.86 | TYK2 (0.53) | NPC1RAB9AFLT1TYK2MAPT | |
| SCHEMBL13960063 | 0.85 | NPC1 (0.44) | NPC1RAB9AFLT1TYK2MAPT | |
| SCHEMBL4068974 | 0.85 | NPC1 (0.43) | CDK1NPC1RAB9AFLT1TYK2 | |
| SCHEMBL4076235 | 0.85 | MAP3K8 (0.43) | NPC1RAB9AFLT1TYK2MAPT | |
| SCHEMBL4007903 | 0.84 | STK17B (0.42) | CDK1NPC1RAB9AFLT1TYK2 | |
| SCHEMBL3929417 | 0.84 | STK17B (0.51) | NPC1RAB9AFLT1EGFRALDH1A1 | |
| SCHEMBL3931001 | 0.83 | IKBKB (0.42) | NPC1RAB9AFLT1TYK2EGFR | |
| SCHEMBL4069817 | 0.81 | CYP1A2 (0.46) | FLT1MAPTEGFRMEN1KMT2A | |
| SCHEMBL4070386 | 0.78 | PDPK1 (0.51) | NPC1RAB9AFLT1MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042913-A1 | Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor | BAYER SCHERING PHARMA AG (DE) | 2009-02-12 | — | — | US | claimed |
| EP-2014662-A1 | Indolyl alkyl thieno-pyrimidyl amines as modulators of EP2 receptors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-01-14 | — | — | EP | claimed |
| US-20090042913-A1 | Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor | BAYER SCHERING PHARMA AG (DE) | 2009-02-12 | — | — | US | disclosed |
| US-20090042913-A1 | Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor | BAYER SCHERING PHARMA AG (DE) | 2009-02-12 | — | — | US | disclosed |
| WO-2009007421-A1 | INDOLYLALKYLTHIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-15 | — | — | WO | disclosed |
| EP-2014662-A1 | Indolyl alkyl thieno-pyrimidyl amines as modulators of EP2 receptors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042913-A1 | Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor | PTGER2, PTGER1, PTGDR2 | CDK1 2619/4885NPC1 2246/4885RAB9A 3318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.